Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio
Proceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).
By
Proceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).
ByProceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).
ByTo be valued at nearly $2.25bn, the combined firm is expected to invest in boosting the biosimilar pipeline.
The merged company will be headquartered in London and led by the current CEO of BenevolentAI.
Teneobio’s three affiliates, TeneoTwo, TeneoFour and TeneoTen, were spun off to its present equity holders.
Sanofi expects the deal to be vital for its mRNA Center of Excellence to unravel mRNA vaccines’ potential.
The funds from the deal will be utilised to build a clinical development organisation that develops low-price novel treatments.
Alexion’s complement-biology platform and pipeline are to be used by AstraZeneca to develop treatments for rare diseases.